Argomenti

Bayesian applications in pharmaceutical studies

Real World Evidence in Health Care Research: How Can It Improve Scientific Knowledge?"

From a Niche to the Headlines: Spotlights on Statistics in Vaccines Development

A deep dive into the Digital Health Revolution

4-5-6 ottobre 2021 9,00 – 13,30

Costo del Forum


100€+IVA per soci SIMeF e studenti 200€+IVA per non soci SIMeF

L'iscrizione va finalizzata entro il 24 settembre 2021 presso la segreteria SIMeF al link: IBIG Forum 2021-Attività SIMeF - Società Italiana di Medicina Farmaceutica

Col contributo educazionale di







IBIG Forum 202



Comitato Scientifico FORUM

Daniele Bottigliengo Marco Costantini Angela Gambioli Luca Grassano Arturo Lanzarotti Andrea Nizzardo Veronica Sciannameo Giulia Zigon



IBIG FORUM

4-6 OCTOBER 2021

AGENDA

DAY 1

Real World Evidence in Health Care Research: How Can It Improve Scientific Knowledge?			
IBIG Moderators: Veronica Sciannameo, Daniele Bottigliengo			
	Title	Speaker	
9.30 - 9.45	Forum presentation and introduction	IBIG	
9.45 - 10.15	Potentialities, opportunities and limitations of the RWE	Sara Cazzaniga, Scientific Partnership Director, IQVIA	
10.15 – 10.45	Population-based genetic association studies and identification of actionable molecular targets: concepts and examples.	Cristian Pattaro, Senior Researcher Eurac Research Institute for Biomedicine, Bolzano	
10.45 - 11.30	Pathway to excelling in real-world evidence generation	Gian Paolo Fadini, Associate Professor of Endocrinology and Metabolism, University of Padua	
11.30 - 11.45	Break		
11.45 - 12.15	ТВС	Lucia Simoni, Medineos, an IQVIA company	
12.15 – 12.45	A multiple imputation procedure for record linkage and causal inference to estimate the effects of home- delivered meals	Roee Gutman, Brown University School of Public Health, Providence	

DAY 2

Bayesian applications in pharmaceutical studies				
IBIG Moderators: Andrea Nizzardo, Angela Gambioli				
	Title	Speaker		
9.00 – 9.15	Introduction	IBIG		
9.15 – 9.45	On the choice of the sample size for evidence and consensus in clinical trials	Fulvio De Santis, Full Professor of Statistics, University of Rome "La Sapienza"		
9.45 – 10.15	Bayesian Adaptive Designs in Early Phase Development	Pantelis Vlachos, VP, Customer Success, Cytel Inc.		
10.15 - 10-45	Overiew of Bayesian Variable Selection methods	Marco Colpo, Senior Biostatistician, Parexel		
10.45 - 11.00	Break			
From a Niche to the Headlines: Spotlights on Statistics in Vaccines Development				
IBIG Moderators: Giulia Zigon, Luca Grassano				
11.00 - 12.00	On the Definition of Vaccine Efficacy and Its Estimation	Mauro Gasparini, Full Professor of Statistics, Politecnico of Turin		
12.00 - 12.30	An Introduction to the Correlate of Protection	Andrea Callegaro, Lead Statistician, GSK		
12.30 - 13.00	A Case Sstudy of a Vaccine Administered to Prevent COPD Exacerbations: Issues and Difficulties of a Study Performed on Patients.	Luca Moraschini, Principal Statistician, GSK		
13.00 - 13.30	Regulatory Perspectives in Vaccine Development	Elisa Marmugi, Global Regulatory Manager, GSK		

DAY 3

A deep dive into the Digital Health Revolution			
IBIG Moderators: Marco Costantini, Arturo Lanzarotti			
	Title	Speaker	
9.00 - 9.15	Introduction	IBIG	
9.15 – 9.45	Technological Innovation at the Service of Research on Chronic and Fragile patients: the SWAN Study Innovative Design – Rationale and Methodology	Chiara Ascardi, Medical Advisor Ophthalmology, Novartis Farma Marta Bartezaghi, Data Analytics Lead, Novartis Farma	
9.45 – 10.15	Technological Innovation at the Service of Research on Chronic and Fragile patients: the SWAN Study Innovative Design – Operational and Technical Development	Diana Stirati, Study Manager Massimo Granata, Innovative Solution Manager,Novartis Farma	
10.15 - 10-45	Standardized Data from Biobanks and Devices to Support Clinical Research and Predictive Medicine: the HIBAD Project	Massimo Beccaria, President, Advice Pharma Group	
10.45 - 11.30	Analysis of physical Activity Data Using Generalized Additive Models: Practical Applications to ALS and COPD Studies	Edoardo Lisi, Statistician, GSK	
11.30-11.45	Break		
11.45 – 12.15	The "Digital Pharmacovigilance"	Ilenia Bocchi, Pharmacovigilance Country Head Deputy, Bayer Lisa Stagi, Patient Safety & Quality Lead, Roche	
12.15 - 12.45	Wrap-up and conclusions	IBIG	